← Leaderboards
Norman L Letvin
Beth Israel Deaconess Medical Center
$50,955,616
Attributed
$50,955,616
Total exposure
34
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $8M · FY2005–14$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$50,955,616 · 34
By mechanism
U19$26,359,323 · 4
UM1$6,215,786 · 2
N01$5,429,484 · 2
R01$4,340,315 · 2
P01$4,008,846 · 5
P51$1,591,013 · 15
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Marcelo J Kuroda$19,353,733
Others in their field
Top investigators on “Macaca Mulatta”
- Barton F Haynes · Duke University$291,595,855
- Peter Gordon Gillespie · Oregon Health And Science University$83,402,374
- Richard A Gibbs · Baylor College Of Medicine$82,928,769
- Dan H. Barouch · Fred Hutchinson Cancer Center$67,567,747
- David I Watkins · George Washington University$57,087,952
- Rama Rao Amara · Emory University$54,145,017
Research focus
Macaca MulattaAids VaccinesVaccinesImmune ResponseCytotoxic T LymphocyteSimian Immunodeficiency VirusRecombinantsVaccine DevelopmentNonhuman PrimateHiv-1VirusT-LymphocyteAntigensCytokineResponseMonkeysFundingCellular ImmunityResearch PersonnelSimian Human Immunodeficiency VirusHuman Immunodeficiency Virus 1GaggingTissue /Cell CultureImmune
Grant awards (72)
Nonhuman primate scientific research support component$1,441,072
UM1 · FY2014 · AI · contact PI
Induction of protective innate immune responses to HIV-1$150,572
UM1 · FY2014 · AI · contact PI
Nonhuman primate scientific research support component$1,679,615
UM1 · FY2013 · AI · contact PI
Induction of protective innate immune responses to HIV-1$108,000
UM1 · FY2013 · AI · contact PI
Nonhuman primate scientific research support component$2,700,027
UM1 · FY2012 · AI · contact PI
Induction of protective innate immune responses to HIV-1$136,500
UM1 · FY2012 · AI · contact PI
NONHUMAN PRIMATE CORE CELLULAR IMMUNOLOGY LABORATORY FOR AIDS$2,540,338
N01 · FY2011 · AI · contact PI
Non-Human Primate Discovery Team$2,190,977
U19 · FY2011 · AI · contact PI
Non-Human Primate Core$1,713,865
U19 · FY2011 · AI · contact PI
Host Genetics Core$1,340,803
U19 · FY2011 · AI · contact PI
RECOMBINANT BCG CANDIDATE VACCINE IMMUNOGENICITY STUDY$68,415
P51 · FY2011 · RR · contact PI
RNA EXPRESSION PROFILES OF SIV-SPECIFIC CD8+ T CELLS$68,415
P51 · FY2011 · RR · contact PI
MOSAIC VACCINE-ELICITED IMMUNE RESPONSES IN RHESUS MONKEYS$68,415
P51 · FY2011 · RR · contact PI
TAS::75 0885::TAS NONHUMAN PRIMATE CORE CELLULAR IMMUNOLOGY LABORATORY FOR AIDS$2,477,572
N01 · FY2010 · AI · contact PI
Non-Human Primate Discovery Team$2,420,318
U19 · FY2010 · AI · contact PI
Host Genetics Core$1,651,833
U19 · FY2010 · AI · contact PI
Non-Human Primate Core$1,243,332
U19 · FY2010 · AI · contact PI
RNA EXPRESSION PROFILES OF SIV-SPECIFIC CD8+ T CELLS$65,759
P51 · FY2010 · RR · contact PI
MOSAIC VACCINE-ELICITED IMMUNE RESPONSES IN RHESUS MONKEYS$65,759
P51 · FY2010 · RR · contact PI
RECOMBINANT MEASLES VIRUS AS HIV-1 VACCINE VECTOR IN RHESUS MONKEYS$65,759
P51 · FY2010 · RR · contact PI
Non-Human Primate Discovery Team$3,034,308
U19 · FY2009 · AI · contact PI
Non-Human Primate Core$929,847
U19 · FY2009 · AI · contact PI
Vector Production Core$774,582
U19 · FY2009 · AI · contact PI
MODELING OF HIV BREAST MILK TRANSMISSION$111,945
P51 · FY2009 · RR · contact PI
IMMUNOGENICITY OF RECOMBINANT BCG VACCINES IN RHESUS MONKEYS$111,945
P51 · FY2009 · RR · contact PI
Non-Human Primate Discovery Team$3,008,534
U19 · FY2008 · AI · contact PI
Consensus Gene-Based Immunogens in Rhesus Monkeys$1,140,185
P01 · FY2008 · AI · contact PI
Non-Human Primate Core$921,983
U19 · FY2008 · AI · contact PI
Vector Production Core$768,040
U19 · FY2008 · AI · contact PI
Immunoregulation in AIDS$658,292
R01 · FY2008 · AI · contact PI
IMMUNOGENICITY OF RECOMBINANT BCG VACCINES IN RHESUS MONKEYS$237,907
P51 · FY2008 · RR · contact PI
Non-Human Primate Discovery Team$2,845,297
U19 · FY2007 · AI · contact PI
Non-Human Primate Core$1,211,044
U19 · FY2007 · AI · contact PI
Vector Production Core$1,090,470
U19 · FY2007 · AI · contact PI
Consensus Gene-Based Immunogens in Rhesus Monkeys$935,034
P01 · FY2007 · AI · contact PI
Immunoregulation in AIDS$592,036
R01 · FY2007 · AI · contact PI
IMMUNOGENICITY OF RECOMBINANT BCG VACCINES IN RHESUS MONKEYS$190,553
P51 · FY2007 · RR · contact PI
Vaccine Production Core$1,214,090
U19 · FY2006 · AI · contact PI
Consensus Gene-Based Immunogens in Rhesus Monkeys$960,504
P01 · FY2006 · AI · contact PI
Immunoregulation in AIDS$530,398
R01 · FY2006 · AI · contact PI
IMMUNOGENICITY OF RECOMBINANT CHIMPANZEE ADENOVIRUS VACCINES IN RHESUS MONKEYS$134,807
P51 · FY2006 · RR · contact PI
Vaccine Production Core$1,214,090
U01 · FY2005 · AI
Immunoregulation in AIDS$660,959
R01 · FY2005 · AI
Consensus Gene-Based Immunogens in Rhesus Monkeys$218,442
P01 · FY2005 · AI
SIV EPITOPE-SPECIFIC CTL RESPONSES IN MAMU-A*01/A*02 DOUBLE-POSITIVES MACAQUES$83,128
P51 · FY2005 · RR
PATHOGENICITY OF SIV VARIANTS THAT ESCAPE CTL RESPONSES IN RHESUS MONKEYS$69,059
P51 · FY2005 · RR
Immunoregulation in AIDS$663,778
R01 · FY2004 · AI
V3 LOOP-SPECIFIC ANTIBODIES AND CONTROL OF SHIV$83,320
P51 · FY2004 · RR
PATHOGENICITY OF SIV VARIANTS THAT ESCAPE CTL RESPONSES IN RHESUS MONKEYS$64,424
P51 · FY2004 · RR
Conference HIV Vaccine Development Progress &Prospects$20,000
R13 · FY2004 · AI
ELICITATION OF SIV-SPECIFIC CYTOTOXIC T CELLS IN RHESUS BY SYSTEMIC VACCINES$101,403
P51 · FY2003 · RR
IMMUNOREGULATION IN AIDS$543,396
R37 · FY2002 · AI
DNA VACCINE IMMUNITY TO HIV1 AND SIV$411,597
R01 · FY2002 · CA
USE OF THE SHIV AND SIV MODELS OF AIDS FOR HIV VACCINE DEVELOPMENT$0
P01 · FY2002 · AI
CORE--ADULT CLINICAL CORE FACILITY$0
P30 · FY2002 · AI
Assessment of Recombinant Chimpanzee Adenovirus Vaccines in Cynomolgous monkeys$0
P01 · FY2002 · AI
NOVEL TECHNOLOGIES FOR MEASURING AIDS VIRUS SPECIFIC CTL IN NONHUMAN PRIMATES$0
P01 · FY2002 · AI
RECOMBINANT POXVIRUS ELICITED CYTOTOXIC T LYMPHOCYTES IN MONKEYS$0
P01 · FY2002 · AI
IMMUNOREGULATION IN AIDS$529,440
R37 · FY2001 · AI
DNA VACCINE IMMUNITY TO HIV1 AND SIV$431,064
R01 · FY2001 · CA
RECOMBINANT POXVIRUS ELICITED CYTOTOXIC T LYMPHOCYTES IN MONKEYS$0
P01 · FY2001 · AI
CORE--ADULT CLINICAL CORE FACILITY$0
P30 · FY2001 · AI
USE OF THE SHIV AND SIV MODELS OF AIDS FOR HIV VACCINE DEVELOPMENT$0
P01 · FY2001 · AI
NOVEL TECHNOLOGIES FOR MEASURING AIDS VIRUS SPECIFIC CTL IN NONHUMAN PRIMATES$0
P01 · FY2001 · AI
RECOMBINANT POXVIRUS ELICITED CYTOTOXIC T LYMPHOCYTES IN MONKEYS$0
P01 · FY2001 · AI
IMMUNOREGULATION IN AIDS$515,890
R37 · FY2000 · AI
PRIMATE IMMUNOLOGY LABORATORY FOR AIDS VACCINE R&D$411,574
N01 · FY2000 · AI
DNA VACCINE IMMUNITY TO HIV1 AND SIV$392,191
R01 · FY2000 · CA
USE OF THE SHIV AND SIV MODELS OF AIDS FOR HIV VACCINE DEVELOPMENT$319,216
P01 · FY2000 · AI
NOVEL TECHNOLOGIES FOR MEASURING AIDS VIRUS SPECIFIC CTL IN NONHUMAN PRIMATES$268,287
P01 · FY2000 · AI
CORE--ADULT CLINICAL CORE FACILITY$188,033
P30 · FY2000 · AI
RECOMBINANT POXVIRUS ELICITED CYTOTOXIC T LYMPHOCYTES IN MONKEYS$167,178
P01 · FY2000 · AI